20.500.12556/DiRROS-15226 Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform Access to a comprehensive molecular alteration screening is patchy in Europe and quality of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European screening platform for patients with thoracic malignancies. Here we report the results of almost 4 years of prospective molecular screening of patients with thoracic malignancies, in terms of quality of the program and molecular alterations identified. Patients with thoracic malignancies at any stage of disease were recruited in SPECTAlung, from June 2015 to May 2019, in 7 different countries. Molecular tumour boards were organised monthly to discuss patients' molecular and clinical profile and possible biomarker-driven treatments, including clinical trial options. FFPE material was collected and analysed for 576 patients with diagnosis of pleural, lung, or thymic malignancies. Ultimately, 539 patients were eligible (93.6%) and 528 patients were assessable (91.7%). The turn-around time for report generation and molecular tumour board was 214 days (median). Targetable molecular alterations were observed in almost 20% of cases, but treatment adaptation was low (3% of patients). SPECTAlung showed the feasibility of a pan-European screening platform. One fifth of the patients had a targetable molecular alteration. Some operational issues were discovered and adapted to improve efficiency. thoracic neoplasms -- Europe lung neoplasms -- Europe diagnostic screening programs -- Europe malignancies lung cancer torakalne novotvorbe -- Evropa pljučne novotvorbe -- Evropa diagnostični presejalni programi -- Evropa malignosti pljučni rak true false true Springer Nature Angleški jezik Ni določen © The Author(s) 2022 Neznano 2022-06-24 12:52:56 2022-06-24 12:52:57 2022-08-21 03:36:09 0000-00-00 00:00:00 2022 0 Velika Britanija 0 Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Urška Janžič; Opis vira z dne 14. 6. 2022; Št. članka: 8342; str. 1-11 Vol. 12 18 May 2022 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-006 2045-2322 10.1038/s41598-022-12056-0 111571715 s41598-022-12056-0.pdf s41598-022-12056-0.pdf 1 1EA8B2AF52F6B1A6FAEB92C782DFB86A 44f7fb99dcdd9184b66dbc69bd8e5660cd7c4bce94f04be47b1e8973e59687e3 f20a7506-17b6-11ed-b6b8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=19974 https://www.nature.com/articles/s41598-022-12056-0.pdf 1 https://dirros.openscience.si/Dokument.php?lang=slv&id=19975 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0